Shengxiang Biotechnology's strategic acquisition of Huasi Wuwei, introducing Academician Dai Hongjie to join

In recent days, Shengxiang Bio (688289), together with Hunan Jinfurong Shengxiang Bio Equity Investment Fund Partnership (Limited Partnership), signed a strategic acquisition agreement with Huas Microbial Technology (Shenzhen) Co., Ltd. (abbreviated as “Huas Microbial”), strategically moving into the grassroots testing and home health monitoring market.

Huas Microbial’s founder, Academician Dai Hongjie, will lead Shengxiang Bio’s global strategic technology and scientific guidance expert team, guiding Shengxiang Bio’s layout of cutting-edge technologies and fundamental scientific research. Shengxiang Bio’s Chairman Dai Lizhong said that Academician Dai Hongjie is one of the very few top scholars worldwide who span the three fields of chemistry, physics, and medicine. This strategic acquisition creates a closed loop that links top scientists’ resources, the transformation of frontier new materials technologies, and the end-to-end layout of products for all scenarios.

According to prior announcements, the transaction consideration for 100% equity of Huas Microbial is 74.714 million yuan, and it will subsequently be included in the scope of Shengxiang Bio’s consolidated financial statements. The agreement provides that Shengxiang Bio and Huas Microbial will carry out in-depth, full-chain cooperation around next-generation in vitro diagnostic products that are precise, highly sensitive, and cost-effective. This specifically includes accelerating the industrialization and rollout of infrared fluorescence technology in in vitro testing, as well as promoting its global adoption.

In the IVD field, Huas Microbial globally holds exclusive core infrared fluorescence technology. Under the premise that product costs are on par with traditional immunofluorescence, infrared fluorescence technology has achieved multiple industry breakthroughs in areas such as precision and anti-interference capability. “This means that within the pricing range that the existing medical payment system can support, its products can deliver a leapfrog improvement in detection performance, and have the technical foundation and commercial viability for large-scale replacement of traditional detection solutions,” Shengxiang Bio said.

At present, Huas Microbial has applied infrared fluorescence technology to a series of immunofluorescence test reagents and supporting instruments for human use and for pet animals, and there is potential for expansion across multiple scenarios. It is expected to open up incremental market space in the IVD industry. These include: grassroots healthcare and veterinary testing scenarios for human use and for pet animals; medical-grade home health monitoring scenarios; and high-frequency, high-value fields such as chronic disease monitoring and critical illness early warning, as well as functional medicine and precise anti-aging.

Dai Lizhong said that this strategic acquisition completes a closed loop of top scientist resources, the transformation of frontier new materials technologies, and the full-scenario product layout. It represents a key strategic move for Shengxiang Bio in the grassroots testing and home health monitoring market. Dai Hongjie said that by participating in and leading the global strategic technology and scientific guidance expert team, he hopes to deeply integrate the accumulation of cutting-edge science with Shengxiang’s industrial advantages. He said this is not only about continuing to break through technical boundaries in professional clinical diagnostics, but also about working together to usher in a new era of “medical-grade home health monitoring.”

Since last year, Shengxiang Bio has completed the acquisition of Shengxiang Haiji, taken a controlling stake in Hong’an Jiyuan, increased capital in Zhenmai Bio, Shengwei Kunteng, and other series of industrial mergers, acquisitions, and strategic investments, and has worked to drive synergistic development effects among the cluster of its investee and shareholding companies. Shengxiang Bio said the company is continuously improving its business layout through both outward M&A and ecological cooperation, with the aim of achieving an all-round extension from the diagnostics domain to the treatment link, and from the domestic market to the global market, while simultaneously enhancing upstream core technology capabilities and downstream scenario coverage capabilities.

Abundant information and precise insights—available in the Sina Finance app.